{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-042903","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.380331+00:00","generated_at":"2026-06-05T18:19:20.865413+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Alaunos Therapeutics VP Finance resigns; Ferdinand Groenewald appointed as replacement via consulting agreement","bullets":["Michael Wong resigned as VP Finance effective Feb 23, 2024.","Ferdinand Groenewald appointed as VP Finance effective Feb 22, 2024 via consulting agreement.","Consulting agreement pays $15,000 per month; indefinite term with 30-day termination notice.","Groenewald previously served as CFO and CAO of Muscle Maker, Inc.; is a CPA.","Agreement includes customary indemnification and business expense reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-042903","json":"https://secwatch.observer/filing/0001193125-24-042903.json","markdown":"https://secwatch.observer/filing/0001193125-24-042903.md","text":"https://secwatch.observer/filing/0001193125-24-042903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/0001193125-24-042903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/d929353d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T18:19:20.865413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0c74318dda","claim":"Michael Wong resigned as Vice President, Finance at Alaunos Therapeutics, Inc..","evidence_excerpt":"On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the \"Company\"), effective February 23, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/0001193125-24-042903-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Vice President, Finance"}],"fact_type":"executive_change"},{"claim_id":"abb2fe9a48","claim":"Ferdinand Groenewald was appointed as Vice President, Finance at Alaunos Therapeutics, Inc..","evidence_excerpt":"On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1107421/000119312524042903/0001193125-24-042903-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Vice President, Finance"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}